3NDM

Crystal structure of Rho-Associated Protein Kinase (ROCK1) with a potent isoquinolone derivative


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 0.310 
  • R-Value Work: 0.241 
  • R-Value Observed: 0.244 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.

Bosanac, T.Hickey, E.R.Ginn, J.Kashem, M.Kerr, S.Kugler, S.Li, X.Olague, A.Schlyer, S.Young, E.R.

(2010) Bioorg Med Chem Lett 20: 3746-3749

  • DOI: 10.1016/j.bmcl.2010.04.069
  • Primary Citation of Related Structures:  
    3NDM

  • PubMed Abstract: 
  • The discovery and SAR of a series of beta-aryl substituted pyrrolidine 2H-isoquinolin-1-one inhibitors of Rho-kinase (ROCK) derived from 2 is herein described. SAR studies have shown that aryl groups in the beta-position are optimal for potency. Our efforts focused on improving the ROCK potency of this isoquinolone class of inhibitors which led to the identification of pyrrolidine 32 which demonstrated a 10-fold improvement in aortic ring (AR) potency over 2 ...

    The discovery and SAR of a series of beta-aryl substituted pyrrolidine 2H-isoquinolin-1-one inhibitors of Rho-kinase (ROCK) derived from 2 is herein described. SAR studies have shown that aryl groups in the beta-position are optimal for potency. Our efforts focused on improving the ROCK potency of this isoquinolone class of inhibitors which led to the identification of pyrrolidine 32 which demonstrated a 10-fold improvement in aortic ring (AR) potency over 2.


    Related Citations: 
    • Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats.
      Ginn, J.D., Bosanac, T., Chen, R., Cywin, C., Hickey, E., Kashem, M., Kerr, S., Kugler, S., Li, X., Prokopowicz, A., Schlyer, S., Smith, J.D., Turner, M.R., Wu, F., Young, E.R.
      (2010) Bioorg Med Chem Lett 20: 5153

    Organizational Affiliation

    Department of Medicinal Chemistry, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA. todd.bosanac@boehringer-ingelheim.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Rho-Associated Protein Kinase (ROCK1) ABCD415Homo sapiensMutation(s): 0 
Gene Names: ROCK1
EC: 2.7.1.37 (PDB Primary Data), 2.7.11.1 (UniProt)
Find proteins for Q13464 (Homo sapiens)
Explore Q13464 
Go to UniProtKB:  Q13464
NIH Common Fund Data Resources
PHAROS:  Q13464
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3ND
Query on 3ND

Download Ideal Coordinates CCD File 
B, C, D
(3S,4R)-N-(7-chloro-1-oxo-1,4-dihydroisoquinolin-6-yl)-4-(4-chlorophenyl)pyrrolidine-3-carboxamide
C20 H17 Cl2 N3 O2
WWMMSIAGRVSGLG-JKSUJKDBSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
3NDIC50 :  11   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 0.310 
  • R-Value Work: 0.241 
  • R-Value Observed: 0.244 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 162.784α = 90
b = 83.553β = 119.95
c = 177.962γ = 90
Software Package:
Software NamePurpose
d*TREKdata scaling
PHENIXrefinement
PDB_EXTRACTdata extraction
MAR345dtbdata collection
d*TREKdata reduction
CNXphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2010-06-07 
  • Released Date: 2010-12-08 
  • Deposition Author(s): Li, X.

Revision History  (Full details and data files)

  • Version 1.0: 2010-12-08
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance